发明名称 |
CO-ADMINISTRATION OF CG250 AND IL-2 OR IFN-ALPHA FOR TREATING CANCER SUCH AS RENAL CELL CARCINOMAS |
摘要 |
A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method is characterized in a significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone, resulting in a positive therapeutic response with respect to that observed with single anti-tumor agents alone.
|
申请公布号 |
US2010008888(A1) |
申请公布日期 |
2010.01.14 |
申请号 |
US20090559839 |
申请日期 |
2009.09.15 |
申请人 |
WILEX AG |
发明人 |
WARNAAR SVEN OLE;ULLRICH STEFAN |
分类号 |
A61K38/00;A61K38/20;A61K38/12;A61K38/17;A61K38/19;A61K38/21;A61K39/395;A61P35/00;A61P43/00;C07K16/30 |
主分类号 |
A61K38/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|